Key therapeutic targets for cancer may play a role in stopping it

Fascin is an actin-packaging protein. FSCN1 is perceived as a competitor biomarker in numerous malignant growth types and as an expected remedial objective.

Now, a new study by researchers at King's College London, Ghent University and AstraZeneca has shown that fascin translocates to the nucleus of cancer cells where it plays a role in cell motility and growth.

"Fascin is an important regulator of F-actin bundling leading to increased filopodia assembly," the researchers wrote.

"Fascin is also overexpressed in most solid tumors where it supports invasion through regulation of F-actin structures in the periphery and nuclear envelope.

Recently, fascin has been identified in the nucleus of a wide range of cells but the contribution of nuclear fascin to cancer cell behavior remains unknown. Here, we show that fascin bundles F-actin into the nucleus to support chromatin organization and efficient DDR.

We have previously shown that fascin resides in the cell's control center – the nucleus – at certain times of the cell's growth cycle,” explained lead author Campbell Lawson, PhD, research associate at the Randall Center for Cell and Molecular Biophysics, King's.